Forecast
The analysts' average price target is €3.64 (-21.04%). The median is €3.64 (-21.04%).
| Buy |
Â
3 |
| Hold |
Â
5 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsIn 2014, Bolt Biotherapeutics has already paid €0.20 in dividends. The last payout was in July 2014.
Financials
In the last quarter, Bolt Biotherapeutics had revenue of €0 and net profit of -€3.9m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -3.9m | 35.87% |
| EBITDA | -3.85m | 34.15% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.01m |
Number of shares | 2.61m |
52-week high/low | €7.08 - €2.82 |
| Dividends | No |
Beta | 1.01 |
P/E ratio | -0.35 |
PEG ratio | 0.01 |
P/B ratio | 1.16 |
P/S ratio | 5.21 |
Company profile
| Name | Bolt Biotherapeutics |
| CEO | William Quinn |
| Headquarters | Redwood City,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 23 |